As Eliquis Sales Lag, Bristol/Pfizer Take Action
The oral anticoagulant generated just $12 million in sales in its first full quarter since it launched in the U.S., lower than expected. Bristol will increase investment in the brand to drive growth.
The oral anticoagulant generated just $12 million in sales in its first full quarter since it launched in the U.S., lower than expected. Bristol will increase investment in the brand to drive growth.